BioAtla Statistics
Total Valuation
BioAtla has a market cap or net worth of $22.13 million. The enterprise value is $10.88 million.
Important Dates
The last earnings date was Thursday, August 7, 2025, after market close.
| Earnings Date | Aug 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
BioAtla has 58.72 million shares outstanding. The number of shares has increased by 11.77% in one year.
| Current Share Class | 58.72M |
| Shares Outstanding | 58.72M |
| Shares Change (YoY) | +11.77% |
| Shares Change (QoQ) | +0.44% |
| Owned by Insiders (%) | 8.32% |
| Owned by Institutions (%) | 16.35% |
| Float | 45.46M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.92 |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.99 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.24
| Current Ratio | 1.24 |
| Quick Ratio | 1.10 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -813.88% and return on invested capital (ROIC) is -353.86%.
| Return on Equity (ROE) | -813.88% |
| Return on Assets (ROA) | -82.52% |
| Return on Invested Capital (ROIC) | -353.86% |
| Return on Capital Employed (ROCE) | -600.43% |
| Revenue Per Employee | $180,328 |
| Profits Per Employee | -$975,656 |
| Employee Count | 61 |
| Asset Turnover | 0.23 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -71.77% in the last 52 weeks. The beta is 0.89, so BioAtla's price volatility has been lower than the market average.
| Beta (5Y) | 0.89 |
| 52-Week Price Change | -71.77% |
| 50-Day Moving Average | 0.39 |
| 200-Day Moving Average | 0.68 |
| Relative Strength Index (RSI) | 55.53 |
| Average Volume (20 Days) | 729,942 |
Short Selling Information
The latest short interest is 3.92 million, so 6.68% of the outstanding shares have been sold short.
| Short Interest | 3.92M |
| Short Previous Month | 4.25M |
| Short % of Shares Out | 6.68% |
| Short % of Float | 8.62% |
| Short Ratio (days to cover) | 5.06 |
Income Statement
In the last 12 months, BioAtla had revenue of $11.00 million and -$59.52 million in losses. Loss per share was -$1.11.
| Revenue | 11.00M |
| Gross Profit | -51.19M |
| Operating Income | -63.22M |
| Pretax Income | -104.56M |
| Net Income | -59.52M |
| EBITDA | -62.47M |
| EBIT | -63.22M |
| Loss Per Share | -$1.11 |
Full Income StatementBalance Sheet
The company has $18.21 million in cash and $6.05 million in debt, giving a net cash position of $12.16 million or $0.21 per share.
| Cash & Cash Equivalents | 18.21M |
| Total Debt | 6.05M |
| Net Cash | 12.16M |
| Net Cash Per Share | $0.21 |
| Equity (Book Value) | -16.75M |
| Book Value Per Share | -0.29 |
| Working Capital | 4.01M |
Full Balance SheetCash Flow
| Operating Cash Flow | -52.32M |
| Capital Expenditures | n/a |
| Free Cash Flow | -52.32M |
| FCF Per Share | -$0.89 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -574.72% |
| Pretax Margin | -541.05% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
BioAtla does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -11.77% |
| Shareholder Yield | -11.77% |
| Earnings Yield | -258.29% |
| FCF Yield | -227.07% |
Analyst Forecast
The average price target for BioAtla is $1.00, which is 165.32% higher than the current price. The consensus rating is "Hold".
| Price Target | $1.00 |
| Price Target Difference | 165.32% |
| Analyst Consensus | Hold |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | 32.38% |
| EPS Growth Forecast (5Y) | -8.36% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BioAtla has an Altman Z-Score of -33.21 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -33.21 |
| Piotroski F-Score | 1 |